Carindacillin

Carindacillin, recognized by the International Nonproprietary Name (INN) and known in the U.S. as Carbenicillin indanyl (USAN), is a penicillin-based antibiotic. It functions as a prodrug of carbenicillin and belongs to the broader class of Beta-lactam antibiotics. The renowned pharmaceutical company, Pfizer, markets Carindacillin under the trademark Geocillin.

Classification[edit]

Type: Penicillin antibiotic
Prodrug of: Carbenicillin

Pharmacology and Usage[edit]

Mechanism of Action[edit]

As a prodrug, Carindacillin is metabolized in the body to produce its active form, carbenicillin. This active antibiotic then targets bacterial cell wall synthesis, disrupting the formation of peptidoglycan chains essential for bacterial cell wall strength and rigidity.

Administration[edit]

Carindacillin is typically administered orally in the form of its sodium salt. This enhances its solubility and ensures effective absorption within the gastrointestinal tract.

Commercial Information[edit]

Brand Name: Geocillin
Manufacturer: Pfizer
Marketing Regions: Carindacillin, under the Geocillin brand, is available in various regions, with specific approval and marketing details varying by jurisdiction.

Safety and Precautions[edit]

Like all antibiotics, it's crucial to complete the full course of Carindacillin, even if symptoms improve before completion. This practice helps prevent antibiotic resistance. Patients with a known allergy to penicillins or other beta-lactam antibiotics should avoid Carindacillin or use it under close medical supervision.

Conclusion[edit]

Carindacillin stands as a significant member of the penicillin antibiotic class, offering an oral route of administration for conditions where carbenicillin's action is desired. Its development and marketing by Pfizer under the Geocillin brand has expanded the range of options available to healthcare professionals in the fight against bacterial infections.